The oncogenic role of Wnt10a in colorectal cancer through activation of canonical Wnt/β‑catenin signaling

Li,Jinlong; Zhang,Zhaoli; Wang,Lixue; Zhang,Yongchen

doi:10.3892/ol.2019.10035

The oncogenic role of Wnt10a in colorectal cancer through activation of canonical Wnt/β‑catenin signaling

Authors:
- Jinlong Li
- Zhaoli Zhang
- Lixue Wang
- Yongchen Zhang
View Affiliations

Affiliations: Department of Laboratory Medicine, The Second Affiliated Hospital of Southeast University, Nanjing, Jiangsu 210003, P.R. China, Department of Pharmacy, The Second Affiliated Hospital of Southeast University, Nanjing, Jiangsu 210003, P.R. China, Department of Oncology, The Second Affiliated Hospital of Southeast University, Nanjing, Jiangsu 210003, P.R. China
Published online on: February 13, 2019 https://doi.org/10.3892/ol.2019.10035
Pages: 3657-3664
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of the major causes of cancer‑associated mortality worldwide. Wnt family member 10A (Wnt10a) is an oncogene associated with the carcinogenesis and progression of renal cell carcinoma, and is strongly expressed in the CRC cell line SW480. However, the role of Wnt10a in CRC has been rarely reported. In the present study, the expression levels of Wnt10a were higher in 40 tumor tissues compared with in paired control tissues, as determined by RT‑qPCR method. In addition, the clinic opathological association analysis indicated that Wnt10a expression was associated with tumor stage (T3+T4, P=0.015). Furthermore, Wnt10a was highly expressed in the SW480, SW620 and HCT116 cell lines. In order to explore the role of Wnt10a in CRC, Wnt10a expression was knocked down by siRNA technology in HCT116 cell line. Cell proliferation was significantly inhibited by 55% in CCK‑8 assay following Wnt10a knockdown and cell migration rate was decreased by 50% in Transwell assay. In addition, western blot analysis demonstrated that Wnt10a knockdown decreased the expression levels of β‑catenin, cyclin D1, lymphoid enhancer‑binding factor 1 and protein kinase B, which was consistent with results obtained with the Wnt/β‑catenin specific inhibitor LGK‑974. It was thus suggested that Wnt10a downregulation inactivated the Wnt/β‑catenin signaling pathway in HCT116 cells. In conclusion, the present study demonstrated that Wnt10a may have an oncogenic role during carcinogenesis of CRC through activation of Wnt/β‑catenin signaling.

View Figures

View References

1	Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics, 2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
2	Pabla B, Bissonnette M and Konda VJ: Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet and the role of chemoprevention. World J Clin Oncol. 6:133–141. 2015. View Article : Google Scholar : PubMed/NCBI
3	Millan M, Merino S, Caro A, Feliu F, Escuder J and Francesch T: Treatment of colorectal cancer in the elderly. World J Gastrointest Oncol. 7:204–220. 2015. View Article : Google Scholar : PubMed/NCBI
4	Applegate CC and Lane MA: Role of retinoids in the prevention and treatment of colorectal cancer. World J Gastrointest Oncol. 7:184–203. 2015. View Article : Google Scholar : PubMed/NCBI
5	Yan Y and Grothey A: Molecular profiling in the treatment of colorectal cancer: Focus on regorafenib. Onco Targets Ther. 8:2949–2957. 2015.PubMed/NCBI
6	Woo IS and Jung YH: Metronomic chemotherapy in metastatic colorectal cancer. Cancer Lett. 400:319–324. 2017. View Article : Google Scholar : PubMed/NCBI
7	Barranha R, Costa JL, Carneiro F and Machado JC: Genetic Heterogeneity in colorectal cancer and its clinical implications. Acta Med Port. 28:370–375. 2015. View Article : Google Scholar : PubMed/NCBI
8	Sherwood V: WNT signaling: An emerging mediator of cancer cell metabolism? Mol Cell Biol. 35:2–10. 2015. View Article : Google Scholar : PubMed/NCBI
9	Hashimoto T, Yamashita S, Yoshida H, Taniguchi H, Ushijima T, Yamada T, Saito Y, Ochiai A, Sekine S and Hiraoka N: WNT pathway gene mutations are associated with the presence of dysplasia in colorectal sessile serrated adenoma/polyps. Am J Surg Pathol. 41:1188–1197. 2017. View Article : Google Scholar : PubMed/NCBI
10	Men XM, Deng B, Tao X, Qi KK and Xu ZW: Wnt gene expression in adult porcine longissimus dorsi and its association with muscle fiber type, energy metabolism, and meat quality. J Integr Agr. 16:144–150. 2017. View Article : Google Scholar
11	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2016. View Article : Google Scholar
12	Nusse R and Clevers H: Wnt/β-catenin signaling, disease and emerging therapeutic modalities. Cell. 169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
13	Mccracken KW, Aihara E, Martin B, Crawford CM, Broda T, Treguier J, Zhang X, Shannon JM, Montrose MH and Wells JM: Wnt/β-catenin promotes gastric fundus specification in mice and humans. Nature. 541:182–187. 2017. View Article : Google Scholar : PubMed/NCBI
14	Arend RC, Londoño-Joshi AI, Straughn JM Jr and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
15	Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, Szczylik C, Pietrucha T, Wieczorek M and Lamparska-Przybysz M: Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res. 17:955–963. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yoshioka S, King ML, Ran S, Okuda H, MacLean JA II, McAsey ME, Sugino N, Brard L, Watabe K and Hayashi K: WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Mol Cancer Res. 10:469–482. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bakker ER, Das AM, Helvensteijn W, Franken PF, Swagemakers S, van der Valk MA, ten Hagen TL, Kuipers EJ, van Veelen W and Smits R: Wnt5a promotes human colon cancer cell migration and invasion but does not augment intestinal tumorigenesis in Apc1638N mice. Carcinogenesis. 34:2629–2638. 2013. View Article : Google Scholar : PubMed/NCBI
18	Galbraith RL, Poole EM, Duggan D, Muehling J, Hsu L, Makar K, Xiao L, Potter JD and Ulrich CM: Polymorphisms in WNT6 and WNT10A and colorectal adenoma risk. Nutr Cancer. 63:558–564. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hsu RJ, Ho JY, Cha TL, Yu DS, Wu CL, Huang WP, Chu P, Chen YH, Chen JT and Yu CP: WNT10A plays an oncogenic role in renal cell carcinoma by activating WNT/beta-catenin pathway. PLoS One. 7:e476492012. View Article : Google Scholar : PubMed/NCBI
20	Kirikoshi H, Inoue S, Sekihara H and Katoh M: Expression of WNT10A in human cancer. Int J Oncol. 19:997–1001. 2011.
21	Kirikoshi H, Sekihara H and Katoh M: WNT10A and WNT6, clustered in human chromosome 2q35 region with head-to-tail manner, are strongly coexpressed in SW480 cells. Biochem Biophys Res Commun. 283:798–805. 2001. View Article : Google Scholar : PubMed/NCBI
22	Cunninghan D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Hanahan D and Weinberg R: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
25	März L and Piso P: Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep. 3:298–302. 2015.
26	Hrckulak D, Kolar M, Strnad H and Korinek V: TCF/LEF transcription factors: An update from the internet resources. Cancer (Basel). 8(pii): E702016. View Article : Google Scholar
27	Yu JS and Cui W: Proliferation, survival and metabolism: The role of PI3K/AKT/mTOR signaling in pluripotency and cell fate determination. Development. 143:3050–3060. 2016. View Article : Google Scholar : PubMed/NCBI
28	Kimmelman AC and White E: Autophagy and tumor metabolism. Cell Metab. 25:1037–1043. 2017. View Article : Google Scholar : PubMed/NCBI
29	Zoncu R, Efeyan A and Sabatini DM: mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar : PubMed/NCBI
30	Bahrami A, Hasanzadeh M, Hassanian SM, ShahidSales S, Ghayour-Mobarhan M, Ferns GA and Avan A: The potential value of the PI3K/Akt/mTOR signaling pathway for assessing prognosis in cervical cancer and as a target for therapy. J Cell Biochem. 118:4163–4169. 2017. View Article : Google Scholar : PubMed/NCBI
31	Yoshida N, Kinugasa T, Ohshima K, Yuge K, Ohchi T, Fujino S, Shiraiwa S, Katagiri M and Akagi Y: Analysis of Wnt and b-catenin expression in advanced colorectal cancer. Anticancer Res. 35:4403–4410. 2015.PubMed/NCBI
32	Zhang X and Hao J: Development of anticancer agents targeting the Wnt/β-catenin signaling. Am J Cancer Res. 5:2344–2360. 2015.PubMed/NCBI
33	Tran FH and Zheng JJ: Modulating the wnt signaling pathway with small molecules. Protein Sci. 26:650–661. 2017. View Article : Google Scholar : PubMed/NCBI